The Susan G Komen Breast Cancer Fo… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1982

Legal Domicile

Phone

9728551600

Tax Period

2024-04-01 to 2025-03-31

The Susan G Komen Breast Cancer Foundation Inc, founded in 1982, is a major nonprofit in the Diseases & Disorders sector that reported $103.2M in total revenue in fiscal year 2024.

Mission

SUSAN G. KOMEN HAS AN UNMATCHED, COMPREHENSIVE 360-DEGREE APPROACH TO FIGHTING BREAST CANCER ACROSS ALL FRONTS AND SUPPORTING MILLIONS OF PEOPLE IN THE U.S. AND IN COUNTRIES WORLDWIDE. WE ADVOCATE FOR POLICIES TO PROTECT PATIENTS, DRIVE RESEARCH BREAKTHROUGHS, IMPROVE ACCESS TO HIGH-QUALITY CARE, OFFER DIRECT PATIENT NAVIGATION AND SUPPORT SERVICES AND EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION. KOMEN REMAINS COMMITTED TO SUPPORTING THOSE AFFECTED BY BREAST CANCER TODAY, WHILE TIRELESSLY SEARCHING FOR TOMORROW'S CURES.

Program Service Accomplishments

Program 1

Expenses: $47,390,113 Revenue: $0

PATIENT CARE: PROVISION OF BREAST HEALTH EDUCATION, BREAST CANCER PATIENT NAVIGATION SERVICES, AND FINANCIAL ASSISTANCE DIRECTLY BY KOMEN TO SUPPORT ACCESS TO SCREENING, DIAGNOSIS, AND TREATMENT...

PATIENT CARE: PROVISION OF BREAST HEALTH EDUCATION, BREAST CANCER PATIENT NAVIGATION SERVICES, AND FINANCIAL ASSISTANCE DIRECTLY BY KOMEN TO SUPPORT ACCESS TO SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS AS WELL AS GRANTS TO OTHER NON-PROFIT ORGANIZATIONS AND THIRD-PARTY CONTRACTS, WITH A FOCUS ON SERVING COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.

Program 2

Expenses: $18,085,047 Revenue: $0

RESEARCH: KOMEN-LED RESEARCH & SCIENTIFIC PROGRAMS AND GRANTS AWARDED TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED-ON RESEARCH PRIORITIES THAT WILL MAKE THE BIGGEST DIFFERENCE FOR PATIENTS: CONQUERING METASTATIC AND AGGRESSIVE BREAST CANCERS, ADVANCING PERSONALIZED BREAST CARE AND ELIMINATING BREAST CANCER DISPARITIES TO IMPROVE OUTCOMES FOR EVERYONE IMPACTED BY BREAST CANCER. SEE SCHEDULE O FOR ADDITIONAL DETAILS.

Program 3

Expenses: $5,753,937 Revenue: $0

PUBLIC POLICY AND ADVOCACY: BREAST CANCER-RELATED INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS...

PUBLIC POLICY AND ADVOCACY: BREAST CANCER-RELATED INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, ENSURE ACCESS TO HIGH-QUALITY AFFORDABLE CARE, ALLEVIATE FINANCIAL AND ADMINISTRATIVE BURDENS AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $102,783,181

Program Service Revenue $0

Investment Income $6,255,060

Other Revenue $-5,883,862

TOTAL REVENUE $103,154,379

Expense Breakdown

Grants Paid $18,581,010

Salaries & Benefits $51,571,757

Fundraising Expenses $26,593,861

Program Expenses $71,229,097

Other Expenses $38,289,701

TOTAL EXPENSES $110,497,282

Year-over-Year Comparison

	2024	2023	Change
Revenue	$103,154,379	$102,934,186	+0.0%
Expenses	$110,497,282	$111,489,604	0.0%
Net Income	$-7,342,903	$-8,555,418	-0.1%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

482

Volunteers

9977

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,384,343

Total Directors

Key Employees

$1,153,664

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Ed Dandridge	Chair of the Board	1.0	Officer Director	$0	$0	$0
Jerri Johnson	Vice Chair	1.0	Officer Director	$0	$0	$0
BJ Schaknowski	BOD Member	1.0	Director	$0	$0	$0
Boris Dolgonos	BOD Member (ending March 2025)	1.0	Director	$0	$0	$0
Charles Rockefeller	BOD Member	1.0	Director	$0	$0	$0
Christina Minnis	BOD Member	1.0	Director	$0	$0	$0
Elizabeth Saint-Aignan	BOD Member	1.0	Director	$0	$0	$0
Gail Heimann	BOD Member	1.0	Director	$0	$0	$0
Julie Gruber	BOD Member	1.0	Director	$0	$0	$0
Kathy Sutherland	BOD Member	1.0	Director	$0	$0	$0
Kim Blackwell	BOD Member	1.0	Director	$0	$0	$0
Kristen Maple	BOD Member (ending March 2025)	1.0	Director	$0	$0	$0
Luke Sauter	BOD Member	1.0	Director	$0	$0	$0
Lydia The	BOD Member (ending March 2025)	1.0	Director	$0	$0	$0
Michelle Bottomley	BOD Member	1.0	Director	$0	$0	$0
Paige Ross	BOD Member (beginning March 2025)	1.0	Director	$0	$0	$0
Peter Brundage	BOD Member	1.0	Director	$0	$0	$0
Robyn Shepherd	BOD Member	1.0	Director	$0	$0	$0
Valerie Rainey	BOD Member	1.0	Director	$0	$0	$0
Eunice Nakamura	General Counsel and Corporate Secretary (Ending Feb-2025)	55.0	Officer	$311,206	$24,533	$335,739
Paula Schneider	President and CEO	55.0	Officer	$658,115	$30,697	$688,812
Ria Williams	Chief Financial Officer	55.0	Officer	$323,478	$36,314	$359,792
Catherine Olivieri	SVP, Human Resources	55.0	Key Emp	$270,792	$27,128	$297,920
Kathryn Watt	SVP, Community Development & Operations	55.0	Key Emp	$265,455	$29,529	$294,984
Sarah Rosales	VP, Corporate Partnerships	55.0	Key Emp	$259,602	$32,314	$291,916
Victoria Smart	SVP, Mission	55.0	Key Emp	$265,909	$2,935	$268,844
Barbara Ducharme	VP, CD Strategy & Midwest Region	55.0	Highest	$202,930	$25,211	$228,141
Kimberly Sabelko	VP, Research & Scientific Programs	55.0	Highest	$203,350	$14,396	$217,746
Megan Klink	VP, CD Strategy & West Region	55.0	Highest	$201,262	$12,414	$213,676
Nicholas Michael DiFranza	VP, Information Technology	55.0	Highest	$254,431	$2,492	$256,923
Timothy A Newman	VP, CD Strategy & South Region	55.0	Highest	$198,810	$7,916	$206,726

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$103,154,379	$110,497,282	$178,872,555	$-7,342,903
2024	$102,934,186	$111,489,604	$188,139,545	$-8,555,418
2023	$107,597,705	$117,063,869	$192,631,082	$-9,466,164
2022	$111,261,456	$100,632,384	$207,354,061	$10,629,072
2021	$87,745,658	$74,767,223	$193,189,248	$12,978,435
2020	$74,786,769	$68,883,829	$151,061,886	$5,902,940
2019	$90,057,799	$92,026,197	$192,149,996	$-1,968,398

The Susan G Komen Breast Cancer Foundation Inc